Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mipomersen Effect on Liver Triglyceride Content
NCT00362180Phase 2Completed
- Sponsor
- Kastle Therapeutics LLC
- Start
- Jul 2006
- Primary completion
- Mar 2010
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mipomersen in hyperlipidemia, familial hypercholesterolemia (FH), mixed dyslipidemia and 1 more (9 cohorts), sponsored by Kastle Therapeutics LLC. Primary endpoint: Change From Baseline in Liver Triglyceride (TG) Content at Day 99. Started Jul 2006; status: completed.
02
Drugs
mipomersen
03
Conditions
hyperlipidemiafamilial hypercholesterolemia (FH)mixed dyslipidemiahepatic steatosis
Beyond the preview
Go deeper on NCT00362180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362180.